Nanoliposomal systems for rapid diagnosis of thrombi by MRI

The research aim of the multidisciplinary project is to develop advanced nanoparticle systems for rapid imaging of thrombi in the cardiovascular system, especially in the brain (cerebral ictus), using in vivo imaging technique MRI. The efficacy of the system will be tested on preclinical rat and rabbit animal models. Contrast agents are based on nanoliposomes labelled with gadolinium complexes for rapid and sensitive imaging with the use of MRI. Targeting of nanoliposomes to thrombi will be achieved by binding of specific ligands to the nanoliposomal surface by means of activated polyethylene glycol spacers. The size of liposomes will be approximately 80 nm. This will ensure their easy penetration through the clot network structure, and decrease penetration to the liver through fenestrations in the endothelial lining of capillary vessels in the hepatic vascular system. RGD peptides will be targeted by specific ligands to both activated thrombocytes and fibrin fibres. New ligands will be protein binders, specifically recognizing fibrin fibres.